HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use JORNAY PM™ safely and effectively. See full prescribing information for JORNAY PM.

WARNING: ABUSE AND DEPENDENCE
See full prescribing information for complete boxed warning.

- CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence (5.1, 9.2, 9.3)
- Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy (5.1, 9.2)

INDICATIONS AND USAGE
JORNAY PM is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. (1)

DOSAGE AND ADMINISTRATION
- JORNAY PM should be taken only in the evening. (2.2)
- Recommended starting dose for patients 6 years and above is 20 mg daily in the evening. (2.2)
- Adjust the timing of administration between 6:30 p.m. and 9:30 p.m. to optimize the tolerability and the efficacy the next morning and throughout the day.
- Dosage may be increased weekly in increments of 20 mg per day up to a maximum daily dose of 100 mg. (2.2)
- Patients are advised to take JORNAY PM consistently either with food or without food. (2.2)
- Capsules may be swallowed whole or opened and the entire contents sprinkled onto applesauce. (2.2)
- To avoid substitution errors and overdosage, do not substitute for other methylphenidate products on a milligram-per-milligram basis. (2.3)

DOSAGE FORMS AND STRENGTHS
Extended-Release Capsules: 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg. JORNAY PM exhibits both delayed-release and extended-release properties. (3, 11)

CONTRAINDICATIONS
- Known hypersensitivity to methylphenidate or product components. (4)
- Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days. (4)

WARNINGS AND PRECAUTIONS
- Serious Cardiovascular Reactions: Sudden death has been reported in association with CNS stimulants at recommended doses in pediatric patients with structural cardiac abnormalities or other serious heart problems. In adults, sudden death, stroke, and myocardial infarction have been reported. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmias, or coronary artery disease. (5.2)
- Blood Pressure and Heart Rate Increases: Monitor blood pressure and pulse. Consider the benefits and risks in patients for whom an increase in blood pressure or heart rate would be problematic. (5.3)
- Psychiatric Adverse Reactions: Use of CNS stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychiatric illness. Evaluate for bipolar disorder prior to JORNAY PM use. (5.4)
- Priapism: Cases of painful and prolonged penile erections and priapism have been reported with methylphenidate products. Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed. (5.5)
- Peripheral Vasculopathy, including Raynaud’s Phenomenon: CNS stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Careful observation for digital changes is necessary during treatment with ADHD stimulants. (5.6)
- Long-Term Suppression of Growth: Monitor height and weight at appropriate intervals in pediatric patients. (5.7)
ADVERSE REACTIONS

Based on accumulated data from other methylphenidate products, the most common (≥5% and twice the rate of placebo) adverse reactions for pediatric patients and adults are: appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased. Additional adverse reactions (≥5% and twice the rate of placebo) in pediatric patients 6 to 12 years treated with JORNAY PM: headache, psychomotor hyperactivity, and mood swings. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Ironshore Pharmaceuticals Inc. at 1-877-938-4766 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 4/2019
FULL PRESCRIBING INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including JORNAY PM™, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2), (9.3)].

1 INDICATIONS AND USAGE

JORNAY PM is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies (14)].

2 DOSAGE AND ADMINISTRATION

2.1 Pretreatment Screening

Prior to treating pediatric patients and adults with CNS stimulants, including JORNAY PM, assess for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions (5.2)].

Assess the risk of abuse prior to prescribing, and monitor for signs of abuse, dependence while on therapy. Maintain careful prescription records, educate patients about abuse, monitor for signs of abuse and overdose, and periodically re-evaluate for the need for JORNAY PM use [see Boxed Warning, Warnings and Precautions (5.1) and Drug Abuse and Dependence (9)].

2.2 General Dosing Information

JORNAY PM is given orally once daily in the evening. JORNAY PM should not be taken in the morning.

The recommended starting dose of JORNAY PM for patients 6 years and older is 20 mg once daily in the evening. The dose may be titrated weekly in increments of 20 mg. Daily doses above 100 mg have not been studied and are not recommended.

Initiate dosing at 8:00 p.m. Adjust the timing of administration between 6:30 p.m. and 9:30 p.m. to optimize the tolerability and efficacy the next morning and throughout the day. In clinical trials of patients aged 6 to 12 years, the most common dosing time (>70% of patients) was 8:00 p.m., with an allowed range between 6:30 p.m. and 9:30 p.m. Following determination of the optimal administration time, advise patients to maintain a consistent dosing time.

Patients who miss their dose of JORNAY PM at the regularly scheduled time should take it as soon as they remember that same evening. If a patient remembers the missed dose the following morning, they should skip the missed dose and wait until their next scheduled evening administration.
Advise patients to take JORNAY PM consistently, either with food or without food.

JORNAY PM may be taken whole, or the capsule may be opened, and the entire contents sprinkled onto applesauce. If the patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the applesauce with sprinkled beads in its entirety without chewing. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken at the same time.

Pharmacological treatment of ADHD may be needed for extended periods. Periodically re-evaluate the long-term use of JORNAY PM and adjust dosage as needed.

2.3 Switching from Other Methylphenidate Products

If switching from other methylphenidate products, discontinue that treatment, and titrate with JORNAY PM using the titration schedule described above.

Do not substitute JORNAY PM for other methylphenidate products on a milligram-per-milligram basis because these products have different pharmacokinetic profiles from JORNAY PM and may have different methylphenidate base composition [see Description (11) and Clinical Pharmacology (12.3)].

2.4 Dose Reduction and Discontinuation

If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage or, if necessary, discontinue the drug. JORNAY PM should be periodically discontinued to assess the child's condition. If improvement is not observed after appropriate dosage adjustment over a one-month period, discontinue drug.

3 DOSAGE FORMS AND STRENGTHS

JORNAY PM (methylphenidate hydrochloride) extended-release capsules exhibit both delayed-release and extended-release properties and are available in the following dose strengths:

- 20 mg capsules with ivory opaque body and light green opaque cap;
- 40 mg capsules with ivory opaque body and blue-green opaque cap;
- 60 mg capsules with white opaque body and powder blue opaque cap;
- 80 mg capsules with white opaque body and light blue opaque cap; and
- 100 mg capsules with white opaque body and dark blue opaque cap.

All capsules are imprinted with the dose in black on the body and “IRONSHORE” in black on the cap, except for the 100 mg capsule, on which “IRONSHORE” is imprinted in white.

4 CONTRAINDICATIONS

JORNAY PM is contraindicated in patients:

- With a history of hypersensitivity to methylphenidate or other components of JORNAY PM. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate products [see Adverse Reactions (6)].
- Receiving concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of a monoamine oxidase inhibitor, because of the risk of hypertensive crisis [see Drug Interactions (7.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Potential for Abuse and Dependence

CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk for medication abuse prior to
prescribing, and monitor for signs of abuse and dependence while on therapy [see Drug Abuse and Dependence (9.2, 9.3)].

5.2 Serious Cardiovascular Reactions
Sudden death, stroke, and myocardial infarction have been reported in adults treated with CNS stimulant treatment at recommended doses. Sudden death has been reported in pediatric patients with structural cardiac abnormalities and other serious cardiac problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, and other serious cardiac problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during treatment with JORNAY PM.

5.3 Blood Pressure and Heart Rate Increases
CNS stimulants may cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm). Individuals may have larger increases. Monitor all patients for hypertension and tachycardia.

5.4 Psychiatric Adverse Reactions
Exacerbation of Pre-existing Psychosis
CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.

Induction of a Manic Episode in Patients with Bipolar Disorder
CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).

New Psychotic or Manic Symptoms
CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. If such occur, consider discontinuing JORNAY PM. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared with 0 in placebo-treated patients.

5.5 Priapism
Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate products in both pediatric patients and adults. Priapism was not reported with drug initiation but developed after some time on the drug, often subsequent to an increase in dose. Priapism has also appeared during a period of drug withdrawal (drug holidays or during discontinuation). Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.

5.6 Peripheral Vasculopathy, including Raynaud's Phenomenon
CNS stimulants, including JORNAY PM, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.
5.7 Long-term Suppression of Growth

CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either methylphenidate or nonmedication-treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and nonmedication-treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated pediatric patients (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development.

Closely monitor growth (weight and height) in pediatric patients treated with CNS stimulants, including JORNAY PM. Patients not growing or gaining height or weight as expected may need to have their treatment interrupted.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Drug Dependence [see Boxed Warning, Warnings and Precautions (5.1), and Drug Abuse and Dependence (9.2, 9.3)]
- Hypersensitivity to methylphenidate or other components of the JORNAY PM [see Contraindications (4)]
- Hypertensive crisis when used concomitantly with monoamine oxidase inhibitors [see Contraindications (4) and Drug Interactions (7.1)]
- Serious Cardiovascular Reactions [see Warnings and Precautions (5.2)]
- Blood Pressure and Heart Rate Increases [see Warnings and Precautions (5.3)]
- Psychiatric Adverse Reactions [see Warnings and Precautions (5.4)]
- Priapism [see Warnings and Precautions (5.5)]
- Peripheral Vasculopathy, including Raynaud's Phenomenon [see Warnings and Precautions (5.6)]
- Long-term Suppression of Growth [see Warnings and Precautions (5.7)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Clinical Trials Experience with Other Methylphenidate Products in Children, Adolescents, and Adults with ADHD

Commonly reported (≥2% of the methylphenidate group and at least twice the rate of the placebo group) adverse reactions from placebo-controlled trials of methylphenidate products include: appetite decreased, weight decreased, nausea, abdominal pain, dyspepsia, dry mouth, vomiting, insomnia, anxiety, nervousness, restlessness, affect lability, agitation, irritability, dizziness, vertigo, tremor, blurred vision, blood pressure increased, heart rate increased, tachycardia, palpitations, hyperhidrosis, and pyrexia.

Clinical Trials Experience with JORNAY PM in Pediatric Patients (6 to 12 years) with ADHD

The safety of JORNAY PM was evaluated in 280 patients (6 to 12 years of age) who participated in two controlled clinical studies of patients with ADHD [see Clinical Studies (14)].

Study 1, conducted in pediatric patients 6 to 12 years of age, was comprised of a 6-week open-label dose-optimization phase in which all patients received JORNAY PM (n=125; mean dose 50 mg), followed by a 1-week, double-blind controlled phase in which patients were randomized to continue JORNAY PM (n=65) or switch to placebo (n=54). During the open-label JORNAY PM treatment phase,
adverse reactions reported in > 5% of patients included: any insomnia (41%), decreased appetite (27%),
affect lability (22%), headache (19%), upper respiratory tract infection (17%), upper abdominal pain
(9%), nausea or vomiting (9%), increased diastolic blood pressure (8%), tachycardia (7%), and
irritability (6%). Three patients discontinued treatment because of adverse reactions of affect lability,
panic attacks, and agitation and aggression. Because of the trial design (6-week open-label active
treatment phase followed by a 1-week, randomized, double-blind, placebo-controlled withdrawal), the
adverse reaction rates described in the double-blind phase are lower than expected in clinical practice.
No difference occurred in the incidence of adverse reactions between JORNAY PM and placebo
during the 1-week, double-blind, placebo-controlled treatment phase.

Study 2 was a 3-week, placebo-controlled study of JORNAY PM (n=81; mean dose 52mg) in pediatric
patients 6 to 12 years.

Most Common Adverse Reactions (incidence of ≥ 5% and at a rate at least twice placebo): any insomnia,
decreased appetite, headache, vomiting, nausea, psychomotor hyperactivity, and affect lability or mood
swings.

One patient in the JORNAY PM group discontinued from the study due to mood swings.

Table 1 provides the incidence of adverse reactions reported in Study 2 (incidence of 2% or more and
at least twice placebo) among pediatric patients 6 to 12 years in a 3-week clinical trial.

<table>
<thead>
<tr>
<th>Body Organ System</th>
<th>Adverse Reaction</th>
<th>JORNAY PM (N=81)</th>
<th>Placebo (N=80)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric disorders</td>
<td>Any insomnia</td>
<td>33%</td>
<td>9%</td>
</tr>
<tr>
<td></td>
<td>Initial insomnia</td>
<td>14%</td>
<td>5%</td>
</tr>
<tr>
<td></td>
<td>Middle insomnia</td>
<td>11%</td>
<td>4%</td>
</tr>
<tr>
<td></td>
<td>Terminal insomnia</td>
<td>11%</td>
<td>1%</td>
</tr>
<tr>
<td></td>
<td>Insomnia, not specified</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td></td>
<td>Affect lability/ Mood swings</td>
<td>6%</td>
<td>1%</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite</td>
<td>19%</td>
<td>4%</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td>10%</td>
<td>5%</td>
</tr>
<tr>
<td></td>
<td>Psychomotor hyperactivity</td>
<td>5%</td>
<td>1%</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Blood pressure diastolic increased</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Vomiting</td>
<td>9%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>6%</td>
<td>0%</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Nasopharyngitis</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td></td>
<td>Pharyngitis streptococcal</td>
<td>3%</td>
<td>0%</td>
</tr>
</tbody>
</table>
| Injury, poisoning and procedural
  complications                           | Contusion                         | 3%               | 0%             |
| Musculoskeletal and connective tissue
  disorders                              | Back pain                         | 3%               | 0%             |
6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of methylphenidate products. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions are as follows:

**Blood and Lymphatic System Disorders:** Pancytopenia, Thrombocytopenia, Thrombocytopenic purpura

**Cardiac Disorders:** Angina pectoris, Bradycardia, Extrasystole, Supraventricular tachycardia, Ventricular extrasystole

**Eye Disorders:** Diplopia, Mydriasis, Visual impairment

**General Disorders:** Chest pain, Chest discomfort, Hyperpyrexia

**Immune System Disorders:** Hypersensitivity reactions such as Angioedema, Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritus, Rashes, Eruptions, and Exanthemas

**Investigations:** Alkaline phosphatase increased, Bilirubin increased, Hepatic enzyme increased, Platelet count decreased, White blood cell count abnormal, Severe hepatic injury

**Musculoskeletal, Connective Tissue and Bone Disorders:** Arthralgia, Myalgia, Muscle twitching, Rhabdomyolysis

**Nervous System Disorders:** Convulsion, Grand mal convulsion, Dyskinesia, Serotonin syndrome in combination with serotonergic drugs

**Psychiatric Disorders:** Disorientation, Hallucination, Hallucination auditory, Hallucination visual, Libido changes, Mania

**Urogenital System:** Priapism

**Skin and Subcutaneous Tissue Disorders:** Alopecia, Erythema

**Vascular Disorders:** Raynaud's phenomenon

7 DRUG INTERACTIONS

7.1 MAO Inhibitors

Do not administer JORNAY PM concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment. Concomitant use of MAO inhibitors and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure [see Contraindications (4)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

**Pregnancy Exposure Registry**

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to JORNAY PM during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.

**Risk Summary**
Published studies and postmarketing reports on methylphenidate use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes [see Data]. No teratogenic effects were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2 and 9 times the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m² basis, respectively. However, spina bifida was observed in rabbits at a dose 31 times the MRHD given to adolescents. A decrease in pup body weight was observed in a pre-and post-natal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5 times the MRHD given to adolescents [see Data].

The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

CNS stimulant medications, such as JORNAY PM, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers.

Data

Human Data

A limited number of pregnancies have been reported in published observational studies and postmarketing reports describing methylphenidate use during pregnancy. Due to the small number of methylphenidate-exposed pregnancies with known outcomes, these data cannot definitely establish or exclude any drug-associated risk during pregnancy. Methodological limitations of these observational studies include small sample size, concomitant use of other medications, lack of detail regarding dose and duration of exposure to methylphenidate and nongeneralizability of the enrolled populations.

Animal Data

In studies conducted in rats and rabbits, methylphenidate was administered orally at doses of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Teratogenic effects (increased incidence of fetal spina bifida) were observed in rabbits at the highest dose, which is approximately 31 times the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m² basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (9 times the MRHD given to adolescents on a mg/m² basis). There was no evidence of specific teratogenic activity in rats, although increased incidences of fetal skeletal variations were seen at the highest dose level (6 times the MRHD given to adolescents on a mg/m² basis), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (2 times the MRHD given to adolescents on a mg/m² basis).

8.2 Lactation

Risk Summary

Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. However, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for JORNAY PM and any potential adverse effects on the breastfed infant from JORNAY PM or from the underlying maternal condition.
Clinical Considerations

Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.

**8.4 Pediatric Use**

The safety and effectiveness of JORNAY PM in pediatric patients less than 6 years have not been established.

The safety and effectiveness of JORNAY PM have been established in pediatric patients ages 6 to 17 years in two adequate and well-controlled clinical studies in pediatric patients 6 to 12 years, pharmacokinetic data in adults, and safety information from other methylphenidate-containing products [see Clinical Studies (14) and see Clinical Pharmacology (12.3)].

The long-term efficacy of methylphenidate in pediatric patients has not been established.

**Long-Term Suppression of Growth**

Growth should be monitored during treatment with stimulants, including JORNAY PM. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.7)].

**Juvenile Animal Toxicity Data**

Rats treated with methylphenidate early in the postnatal period through sexual maturation demonstrated a decrease in spontaneous locomotor activity in adulthood. A deficit in acquisition of a specific learning task was observed in females only. The doses at which these findings were observed are at least 2.5 times the maximum recommended human dose (MRHD) of 100 mg/day given to children on a mg/m$^2$ basis.

In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal week 10). When these animals were tested as adults (postnatal weeks 13-14), decreased spontaneous locomotor activity was observed in males and females previously treated with $\geq 50$ mg/kg/day (approximately $\geq 2.5$ times the MRHD of 100 mg/day given to children on a mg/m$^2$ basis), and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose (5 times the MRHD of 100 mg/day given to children on a mg/m$^2$ basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (0.25 times the MRHD of 100 mg/day given to children on a mg/m$^2$ basis). The clinical significance of the long-term behavioral effects observed in rats is unknown.

**8.5 Geriatric Use**

JORNAY PM has not been studied in patients older than 65 years of age.

**9 DRUG ABUSE AND DEPENDENCE**

**9.1 Controlled Substance**

JORNAY PM contains methylphenidate, a Schedule II controlled substance.

**9.2 Abuse**

CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse. Abuse is characterized by impaired control over drug use, compulsive use, continued use despite harm, and craving.

Signs and symptoms of CNS stimulant abuse include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss
of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed. Abusers of CNS stimulants may chew, snort, inject, or use other unapproved routes of administration, which can result in overdose and death [see Overdosage (10)].

To reduce the abuse of CNS stimulants including JORNAY PM, assess the risk of abuse prior to prescribing. After prescribing, keep careful prescription records, educate patients and their families about abuse and on proper storage and disposal of CNS stimulants [see How Supplied/Storage and Handling (16)], monitor for signs of abuse while on therapy, and re-evaluate the need for JORNAY PM use.

9.3 Dependence

Tolerance

Tolerance (a state of adaptation in which exposure to a drug results in a reduction of the drug's desired and/or undesired effects over time) can occur during chronic therapy with CNS stimulants including JORNAY PM.

Dependence

Physical dependence (a state of adaptation manifested by a withdrawal syndrome produced by abrupt cessation, rapid dose reduction, or administration of an antagonist) can occur in patients treated with CNS stimulants, including JORNAY PM. Withdrawal symptoms after abrupt cessation following prolonged high-dosage administration of CNS stimulants include: dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

10 OVERDOSAGE

10.1 Signs and Symptoms

Signs and symptoms of acute methylphenidate overdose, resulting principally from overstimulation of the CNS and from excessive sympathomimetic effects, may include the following: nausea, vomiting, diarrhea, restlessness, anxiety, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, hypotension, tachypnea, mydriasis, dryness of mucous membranes, and rhabdomyolysis.

10.2 Management of Overdose

Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice on the management of overdose with methylphenidate. Provide supportive care, including close medical supervision and monitoring. Treatment should consist of those general measures employed in the management of overdose with any drug. Consider the possibility of multiple drug overdosages. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. Use supportive and symptomatic measures.

11 DESCRIPTION

JORNAY PM contains methylphenidate hydrochloride, a central nervous system (CNS) stimulant. Methylphenidate hydrochloride is a white, odorless crystalline powder. Its aqueous solutions are acidic. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. The chemical name of methylphenidate hydrochloride is d,l (racemic) methyl α-phenyl-2-piperidineacetate hydrochloride. Its molecular formula is C_{14}H_{19}NO_{2}•HCl and the molecular weight is 269.77. Its structural formula is
The molecular formula of the free base is C₁₄H₁₉NO₂ and its molecular weight is 233.31.

JORNAY PM extended-release capsules contain beads with two functional film coatings (outer delayed-release and inner extended-release) surrounding a drug core coated with methylphenidate hydrochloride. The outer, delayed-release coating delays the initial release of methylphenidate while the inner extended-release coating controls the release throughout the day. JORNAY PM is available as extended-release capsules for oral use in five strengths. Each capsule contains 20 mg, 40 mg, 60 mg, 80 mg, or 100 mg of methylphenidate hydrochloride, which is equivalent to 17.4 mg, 34.8 mg, 52.2 mg, 69.6 mg, or 87.0 mg of methylphenidate free base, respectively.

JORNAY PM capsules also contain the following inactive ingredients: dibutyl sebacate, diglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose, magnesium stearate, methacrylic acid copolymer Type B, microcrystalline cellulose, monoglycerides, polysorbate 80, and talc. The capsule shell of 20 and 40 mg strength capsules is made of FD&C Blue #1, hypromellose, titanium dioxide, yellow iron oxide, and black ink for the imprint. The capsule shell of 60 and 80 mg strength capsules is made of FD&C Blue #1, hypromellose, titanium dioxide, and black ink for the imprint. The capsule shell of 100 mg strength capsule is made of black iron oxide, FD&C Blue #1, hypromellose, red iron oxide, titanium dioxide, and black ink, and white ink for the imprint.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. The exact mode of therapeutic action in ADHD is not known.

12.2 Pharmacodynamics

Methylphenidate is a racemic mixture comprising the d- and l-isomers. The d-isomer is more pharmacologically active than the l-isomer. Methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

12.3 Pharmacokinetics

The pharmacokinetics of methylphenidate was dose-proportional between 20 mg and 100 mg dose level.

Absorption

The pharmacokinetics of methylphenidate after a single, 100 mg oral dose of JORNAY PM administered in the evening at 9 pm were studied in healthy adults. The initial absorption of methylphenidate into plasma is delayed such that no more than 5% of total drug is available within the first 10 hours after dosing. After the lag period, the absorption of methylphenidate occurs in a single peak with a median T_{max} 14.0 hours, followed by a gradual decline throughout the rest of the day.

Figure 1: Arithmetic Mean Plasma Methylphenidate Concentrations following a Single, Oral, 100 mg Dose of JORNAY PM (Methylphenidate Hydrochloride Extended-Release Capsule) or Methylphenidate Immediate-Release Oral Product Administered in a Crossover Manner to Healthy Adult Subjects
The relative bioavailability of JORNAY PM (given once a day) compared to the same daily dose of a methylphenidate immediate-release oral product (given 3 times a day) in adults is 73.9%.

**Food Effects**

Compared to the fasted state, JORNAY PM taken with a high-fat meal at night exhibited similar mean $AUC_{0-\infty}$, a 14% lower mean $C_{max}$, and a median $T_{max}$ extended by approximately 2.5 hours. After JORNAY PM was taken at night, a morning meal had no effect on the pharmacokinetics of methylphenidate.

The pharmacokinetic parameters were similar when JORNAY PM was taken as a whole capsule or when sprinkled on applesauce.

**Elimination**

The apparent half-life of methylphenidate in adults following oral administration of JORNAY PM was approximately 5.9 hours.

**Metabolism**

In humans, methylphenidate is metabolized primarily by de-esterification to α-phenyl-piperidine acetic acid (PPAA). The metabolite has little pharmacologic activity.

**Excretion**

After oral dosing of radiolabeled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was PPAA, accounting for approximately 80% of the dose.

**Alcohol Effect:**

*In vitro* testing showed that approximately 97% of methylphenidate was released from JORNAY PM capsules in 2 hours in the presence of 40% alcohol. The increase in methylphenidate release rate was not observed in the presence of 5 to 20% alcohol. No *in vivo* studies have been conducted to assess the effect of alcohol on drug exposure.
Specific populations:

Pediatric Patients
The pharmacokinetics of methylphenidate after a single, 54 mg oral dose of JORNAY PM administered in the evening at 9 pm were studied in two separate studies in adults and in children and adolescent patients with ADHD between 8 and 17 years of age. The plasma methylphenidate concentration curves were qualitatively similar in healthy adult volunteers, children 8 to 12 years, and adolescents with ADHD. Body weight dose normalized AUC and \( C_{\text{max}} \) were similar in children, adolescents, and adults. However, there were differences in mean PK parameters between children, adolescents, and adults; children were exposed to higher levels of methylphenidate when provided the same dose of JORNAY PM (\( C_{\text{max}} \): children = 11.6 ng/mL, adolescents = 7.2 ng/mL, adults = 6.0 ng/mL; \( \text{AUC}_{\text{t}} \): children = 206 ng·hr/mL, adolescents = 106 ng·hr/mL, adults = 83.4 ng·hr/mL).

Patients with Renal Impairment:
There is no experience with the use of JORNAY PM in patients with renal insufficiency. After oral administration of radiolabeled methylphenidate in humans, methylphenidate was extensively metabolized and approximately 80% of the radioactivity was excreted in the urine in the form of PPAA. Since renal clearance is not an important route of methylphenidate clearance, renal insufficiency is expected to have little effect on the pharmacokinetics of JORNAY PM.

Patients with Hepatic Impairment
There is no experience with the use of JORNAY PM in patients with hepatic insufficiency.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis:
In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dose of approximately 60 mg/kg/day. This dose is approximately 1.5 times the maximum recommended human dose (MRHD) of 100 mg/day given to children on a mg/m\(^2\) basis. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown.

Methylphenidate did not cause any increases in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day, which is approximately 2 times the MRHD (children) on a mg/m\(^2\) basis.

In a 24-week carcinogenicity study in the transgenic mouse strain p53\(^{+/−}\), which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. Male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dose groups were exposed to 60 to 74 mg/kg/day of methylphenidate.

Mutagenesis:
Methylphenidate was not mutagenic in the in vitro Ames reverse mutation assay or in the in vitro mouse lymphoma cell forward mutation assay. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an in vitro assay in cultured Chinese Hamster Ovary (CHO) cells. Methylphenidate was negative in vivo in males and females in the mouse bone marrow micronucleus assay.

Impairment of Fertility:
Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in
an 18-week continuous breeding study. The study was conducted at doses up to 160 mg/kg/day, approximately 6-times the maximum recommended human dose of 100 mg/day given to adolescents on a mg/m² basis.

14 CLINICAL STUDIES

The efficacy of JORNAY PM was established in two clinical studies of JORNAY PM in pediatric patients 6 to 12 years of age (N = 278) who met DSM-5 criteria for ADHD inattentive, hyperactive-impulsive, or combined inattentive/hyperactive-impulsive subtypes.

Study 1 (NCT#02493777), conducted in pediatric patients 6 to 12 years of age, was comprised of a 6-week, open-label, dose-optimization phase in which all patients (n = 117) received JORNAY PM (once each evening; flexible dosing from 20 mg to 100 mg), followed by a 1-week, double-blind, placebo-controlled withdrawal phase in which patients were randomized to continue JORNAY PM (n=64; mean dose 67 mg) or switch to placebo (n=53). After 1 week of double-blind treatment, patients were evaluated in an analog classroom over a 12-hour period using the Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP), a 13-item teacher-rated scale that assesses manifestations of ADHD in a classroom setting. Possible scores range from 0 (normal/no impairment) to 78 (maximal impairment). The primary efficacy endpoint was the model-adjusted average of all post-dose SKAMP combined scores measured during the 12-hour analog testing period from 8:00 a.m. to 8:00 p.m. The secondary efficacy measure was the morning subscale of the Parent Rating of Evening and Morning Behavior-Revised (PREMB-R AM), to measure manifestations of ADHD in the early morning. This clinician-rated scale is based on parent interview using three questions and assesses manifestations of ADHD during the early morning period. Possible scores range from 0 (no ADHD manifestations) to 9 (severe ADHD manifestations).

The primary efficacy endpoint, the model-adjusted average of all post-dose SKAMP combined scores measured during the 12-hour analog testing period, was statistically significantly better (lower) for JORNAY PM compared with placebo (Table 2). JORNAY PM showed improvement over placebo at time points (9 and 10 a.m., and 12, 2, 4, 6 and 7 p.m.) on the next day after the evening dosing. Figure 2 shows the LS mean and standard error of SKAMP combined scores at each of the individual time points from 8:00 a.m. to 8:00 p.m. The secondary efficacy endpoint, the PREMB-R AM, was also statistically significantly better (lower) for JORNAY PM versus placebo.

Study 2 (NCT#02520388) was a 3-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in pediatric patients, 6 to 12 years of age. Patients were randomized to an evening dose of 40, 60, or 80 mg JORNAY PM (n=81) or placebo (n=80). The primary efficacy measure was the ADHD Rating Scale (ADHD-RS-IV) Total Score, measuring severity of manifestations throughout the day. Possible scores range from 0 (no ADHD manifestations) to 54 (severe symptoms of both ADHD subtypes). Normative scores range 18 to 29 in ADHD. The secondary efficacy measure was the Before School Functioning Questionnaire (BSFQ), a clinician-rated 20-item questionnaire assessing ADHD manifestations on a severity scale of 0 to 3. BSFQ is intended to assess early morning before school activities from the time the child awakens and some behaviors not specific to early morning. Possible scores range from 0 (no difficulty) to 60 (severe difficulty).

After 3 weeks of treatment, the ADHD-RS-IV total scores were statistically significantly better (lower) for JORNAY PM than placebo (Table 2). The secondary efficacy endpoint, the BSFQ, was also statistically significantly better (lower) for JORNAY PM versus placebo.

Table 2 summarizes the primary endpoint results for Study 1 and Study 2.

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Mean Baseline</th>
<th>LS Mean Placebo-subtracted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Summary of Primary Efficacy Results in Pediatric Patients (6 – 12 years) with ADHD (Studies 1 and 2)
<table>
<thead>
<tr>
<th>Study</th>
<th>Measure (Primary Endpoint)</th>
<th>Group</th>
<th>Baseline Score (SD)</th>
<th>LS Mean (SE)</th>
<th>Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>SKAMP CS Average</td>
<td>JORNAY PM (64)</td>
<td>NA</td>
<td>14.8 (1.17)</td>
<td>-5.9 (-9.1, -2.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo (53)</td>
<td>NA</td>
<td>20.7 (1.22)</td>
<td></td>
</tr>
<tr>
<td>Study 2</td>
<td>ADHD-RS-IV</td>
<td>JORNAY PM (81)</td>
<td>43.1 (7.33)</td>
<td>24.1 (1.50)</td>
<td>-7.0 (-11.4, -2.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo (80)</td>
<td>43.5 (6.84)</td>
<td>31.2 (1.60)</td>
<td></td>
</tr>
</tbody>
</table>

CS: Combined Score (sum of items 1-13)

Figure 2: Study 1—LS Mean SKAMP Combined Score on Day after Final Treatment, as Measured in an Analogue Classroom, N=117

16 HOW SUPPLIED/STORAGE AND HANDLING

JORNAY PM (methylphenidate hydrochloride) extended-release capsules are available as follows:

**20 mg Capsules** – ivory opaque body and light green opaque cap (imprinted with “20 mg” in black on the body and “IRONSHORE” in black on the cap)

Bottles of 100................................................................................................................NDC 71376-201-03

**40 mg Capsules** – ivory opaque body and blue-green opaque cap (imprinted with “40 mg” in black on the body and “IRONSHORE” in black on the cap)

Bottles of 100................................................................................................................NDC 71376-202-03

**60 mg Capsules** – white opaque body and powder blue opaque cap (imprinted with “60 mg” in black on
the body and “IRONSHORE” in black on the cap)

80 mg Capsules – white opaque body and light blue opaque cap (imprinted with “80 mg” in black on the body and “IRONSHORE” in black on the cap)

100 mg Capsules – white opaque body and dark blue opaque cap (imprinted with “100 mg” in black on the body and “IRONSHORE” in white on the cap)

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from humidity.

Disposal

Comply with local laws and regulations on drug disposal of CNS stimulants. Dispose of remaining, unused, or expired JORNAY PM by a medicine take-back program or by an authorized collector registered with the Drug Enforcement Administration. If no take-back program or authorized collector is available, mix JORNAY PM with an undesirable, nontoxic substance to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and discard JORNAY PM in the household trash.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Controlled Substance Status/Potential for Abuse and Dependence

Advise patients that JORNAY PM is a federally controlled substance, and it can be abused or lead to dependence [see Drug Abuse and Dependence (9.1, 9.2, 9.3)]. Instruct patients that they should not give JORNAY PM to anyone else. Advise patients to store JORNAY PM in a safe place, preferably locked, to prevent abuse. Advise patients to comply with laws and regulations on drug disposal. Advise patients to dispose of remaining, unused, or expired JORNAY PM through a medicine take-back program if available [Warnings and Precautions (5.1), Abuse and Dependence (9.2, 9.3), How Supplied/Storage and Handling (16)].

Dosage and Administration Instructions

Advise patients that JORNAY PM is taken once daily in the evening. Advise patients that JORNAY PM should not be taken in the morning. It should be taken consistently, either with food or without food, and patients should establish a routine pattern of administration time.

For patients who take JORNAY PM sprinkled over applesauce, the contents of the entire capsule should be consumed immediately; it should not be stored. Patients should take the applesauce with sprinkled beads in its entirety without chewing. When initiating treatment with JORNAY PM, provide dosage escalation and administration instructions [see Dosage and Administration (2)].

Advise patients that if they forget to take JORNAY PM at their regularly scheduled time, they may take it as soon as they remember that same evening. If a patient remembers the following morning that they forgot to take their JORNAY PM dose the evening before, advise the patient to wait until their next scheduled evening administration.

Serious Cardiovascular Risks
Advise patients that there is a potential for serious cardiovascular risks including sudden death, myocardial infarction, stroke, and hypertension with JORNAY PM use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease [see Warnings and Precautions (5.2)].

**Blood Pressure and Heart Rate Increases**

Advise patients that JORNAY PM can cause elevations in blood pressure and heart rate [see Warnings and Precautions (5.3)].

**Psychiatric Risks**

Advise patients that JORNAY PM, at recommended doses, can cause psychotic or manic symptoms, even in patients without a prior history of psychotic symptoms or mania [see Warnings and Precautions (5.4)].

**Priapism**

Advise patients, caregivers, and family members of the possibility of painful or prolonged penile erections (priapism). Instruct the patient to seek immediate medical attention in the event of priapism [see Warnings and Precautions (5.5)].

**Circulation Problems in Fingers and Toes [peripheral vasculopathy, including Raynaud's phenomenon]**

- Instruct patients about the risk of peripheral vasculopathy, including Raynaud's phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change from pale, to blue, to red.
- Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.
- Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking JORNAY PM.
- Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients [see Warnings and Precautions (5.6)].

**Suppression of Growth**

Advise patients, caregivers, and family members that JORNAY PM can cause slowing of growth and weight loss [see Warnings and Precautions (5.7)].

**Alcohol Effect**

Advise patients to avoid alcohol, while taking JORNAY PM. Consumption of alcohol while taking JORNAY PM may result in a more rapid release of the dose of methylphenidate [see Clinical Pharmacology (12.3)].

**Pregnancy Registry**

Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to JORNAY PM during pregnancy [see Use in Specific Populations (8.1)].

Packaged by:
Patheon Puerto Rico, Inc.
Manatí, Puerto Rico, 00674 USA

Manufactured for:
Ironshore Pharmaceuticals, Inc.
Cherry Hill, NJ, 08002 USA
What is the most important information I should know about JORNAY PM?

JORNAY PM can cause serious side effects, including:

- **Abuse and dependence.** JORNAY PM contains methylphenidate. JORNAY PM, other methylphenidate containing products, and amphetamines, have a high chance for abuse and can cause physical and psychological dependence. Your healthcare provider should check you or your child for signs of abuse and dependence before and during treatment with JORNAY PM.

  - Tell your healthcare provider if you or your child has ever abused or been dependent on alcohol, prescription medicines, or street drugs.
  - Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.

- **Heart-related problems, including:**
  - sudden death, stroke, and heart attack in adults
  - sudden death in children who have heart problems or heart defects
  - increased blood pressure and heart rate

  Your healthcare provider should check you or your child carefully for heart problems before starting JORNAY PM. Tell your healthcare provider if you or your child has any heart problems, heart defects, or high blood pressure.

  Your healthcare provider should check you or your child's blood pressure and heart rate regularly during treatment with JORNAY PM.

  **Call your healthcare provider right away or go to the nearest hospital emergency room right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with JORNAY PM.**

- **Mental (psychiatric) problems, including:**
  - new or worse behavior and thought problems
  - new or worse bipolar illness
  - new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms

  Tell your healthcare provider about any mental problems you or your child has, or about a family history of suicide, bipolar illness, or depression.

  **Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems during treatment with JORNAY PM, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.**

What is JORNAY PM?

JORNAY PM is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity in people 6 years of age and older with ADHD.

It is not known if JORNAY PM is safe and effective in children under 6 years of age.

**JORNAY PM is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs.** Keep JORNAY PM in a safe place to protect it from theft. Never give your JORNAY PM to anyone else, because it may cause death or harm them. Selling or giving away JORNAY PM may harm others, and is against the law.

Who should not take JORNAY PM?

Do not take JORNAY PM if you or your child is:

- allergic to methylphenidate hydrochloride, or any of the ingredients in JORNAY PM. See the end of this Medication Guide for a complete list of ingredients in JORNAY PM.
- taking or has taken within the last 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI).

Before taking JORNAY PM, tell your or your child's healthcare provider about all medical
conditions, including if you or your child:

- have heart problems, heart defects, or high blood pressure
- have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression
- have circulation problems in fingers or toes
- are pregnant or plan to become pregnant. It is not known whether JORNAY PM will harm your unborn baby.
  - There is a pregnancy registry for females who are exposed to JORNAY PM during pregnancy. The purpose of the registry is to collect information about the health of females exposed to JORNAY PM and their baby. If you or your child becomes pregnant during treatment with JORNAY PM, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants. You can register by calling 1-866-961-2388.
- are breastfeeding or plan to breastfeed. JORNAY PM passes into breast milk. Talk to your healthcare provider about the best way to feed the baby during treatment with JORNAY PM.

Tell your healthcare provider about all of the medicines that you or your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. JORNAY PM and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted during treatment with JORNAY PM. Your healthcare provider will decide whether JORNAY PM can be taken with other medicines. Especially tell your healthcare provider if you or your child takes medicine to treat depression, including MAOIs.

Know the medicines that you or your child takes. Keep a list of the medicines with you to show your healthcare provider and pharmacist when you or your child get a new medicine. Do not start any new medicine during treatment with JORNAY PM without talking to your or your child’s healthcare provider first.

How should JORNAY PM be taken?

- Take JORNAY PM exactly as prescribed by your healthcare provider.
- Your healthcare provider may change the dose and timing of the JORNAY PM dose if needed.
- Take JORNAY PM by mouth 1 time each day in the evening between 6:30 p.m. and 9:30 p.m.
- Take JORNAY PM at the same time each evening. JORNAY PM should not be taken in the morning.
- JORNAY PM can be taken with or without food, but take it the same way each time.
- JORNAY PM capsules may be swallowed whole, or if JORNAY PM capsules cannot be swallowed whole, the capsules may be opened and sprinkled onto applesauce. Make sure to sprinkle all the JORNAY PM onto the applesauce. The JORNAY PM dose should not be divided.
  - swallow all the applesauce and medicine mixture right away
  - do not chew the applesauce and medicine mixture
  - do not store the applesauce and medicine mixture
- Your healthcare provider may sometimes stop JORNAY PM treatment for a while to check for ADHD symptoms.
- If a dose of JORNAY PM is missed, it should be taken as soon as you remember the same evening. If you do not remember until the next morning you should not take the dose. Wait until that evening to take the next scheduled dose. A missed dose should not be taken in the morning.
- If you or your child takes too much JORNAY PM, call your healthcare provider or go to the nearest hospital emergency room right away.

What should be avoided during treatment with JORNAY PM?

- Avoid drinking alcohol during treatment with JORNAY PM. This may cause a faster release of the JORNAY PM medicine.

What are possible side effects of JORNAY PM?
JORNAY PM can cause serious side effects, including:

- See “What is the most important information I should know about JORNAY PM?”
- **Painful and prolonged erections (priapism).** Priapism has happened in males who take products that contain methylphenidate. If you or your child develops priapism, get medical help right away.
- **Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud's phenomenon).** Signs and symptoms may include:
  - fingers or toes may feel numb, cool, or painful
  - fingers or toes may change color from pale, to blue, to red
Tell your healthcare provider if you or your child has numbness, pain, skin color change, or sensitivity to temperature in the fingers or toes.

**Call your healthcare provider right away if you or your child has any signs of unexplained wounds appearing on fingers or toes during treatment with JORNAY PM.**

- **Slowing of growth (height and weight) in children.** Children should have their height and weight checked often during treatment with JORNAY PM. JORNAY PM treatment may be stopped if your child is not gaining weight or height.

The most common side effects of methylphenidate products in children, adolescents, and adults with ADHD include:

- decreased appetite
- trouble sleeping
- nausea
- vomiting
- indigestion
- stomach pain
- weight loss
- anxiety
- dizziness
- irritability
- mood swings (affect liability)
- increased heart rate
- increased blood pressure

The most common side effects of JORNAY PM, in children age 6 to 12 with ADHD include:

- trouble sleeping
- decreased appetite
-restlessness (psychomotor hyperactivity)
- headache
- nausea
- mood swings
- vomiting

These are not all the possible side effects of JORNAY PM. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store JORNAY PM?**

- Store JORNAY PM at room temperature between 68°F to 77°F (20°C to 25°C).
- Store JORNAY PM in a safe place, like a locked cabinet. Protect from humidity.
- Dispose of remaining, unused, or expired JORNAY PM by a medicine take-back program at authorized collection sites such as retail pharmacies, hospital or clinic pharmacies, and law enforcement locations. If no take-back program or authorized collector is available, mix JORNAY PM with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away JORNAY PM in the household trash.

**Keep JORNAY PM and all medicines out of the reach of children.**

**General information about the safe and effective use of JORNAY PM.**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use JORNAY PM for a condition for which it was not prescribed. Do not give JORNAY PM to other people, even if they have the same symptoms. It may harm them, and it is against the law.

You can ask your doctor or pharmacist for information about JORNAY PM that is written for healthcare professionals.

**What are the ingredients in JORNAY PM?**
**Active Ingredient:** methylphenidate hydrochloride

**Inactive Ingredients:** dibutyl sebacate, diglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose, magnesium stearate, methacrylic acid copolymer Type B, microcrystalline cellulose, monoglycerides, polysorbate 80, and talc.

The capsule shell of 20 and 40 mg strength capsules contains FD&C Blue #1, hypromellose, titanium dioxide, yellow iron oxide, and black ink for the imprint. The capsule shell of 60 and 80 mg strength capsules contains FD&C Blue #1, hypromellose, titanium dioxide, and black ink for the imprint. The capsules shell of 100 mg strength capsule contains black iron oxide, FD&C Blue#1, hypromellose, red iron oxide, titanium dioxide, black ink, and white ink for the imprint.

Manufactured for Ironshore Pharmaceuticals, Inc.: For more information about JORNAY PM go to www.jornaypm.com or call 1-877-938-4766.

This Medication Guide has been approved by the U.S. Food and Drug Administration

---

**Principal Display Panel - Jornay PM™ 20 mg Bottle Label**

NDC 71376-201-03

Take Only In The Evening

Jornay PM™ CII

[methylphenidate hydrochloride]

Extended-Release Capsules

20 mg

Attention Pharmacist: Dispense the accompanying Medication Guide to each patient.

Rx Only

100 Capsules

---

**Principal Display Panel - Jornay PM™ 40 mg Bottle Label**

NDC 71376-202-03

Take Only In The Evening

Jornay PM™ CII

[methylphenidate hydrochloride]

Extended-Release Capsules

---
Attention Pharmacist: Dispense the accompanying Medication Guide to each patient.

Rx Only

100 Capsules

Jornay PM™ 60 mg Bottle Label

NDC 71376-203-03

Take Only In The Evening

Jornay PM™ CII

[methylphenidate hydrochloride]

Extended-Release Capsules

60 mg

Attention Pharmacist: Dispense the accompanying Medication Guide to each patient.

Rx Only

100 Capsules
Jornay PM™
[methylphenidate hydrochloride]
Extended-Release Capsules

60 mg

Take Only In The Evening

Attention Pharmacist: Dispense the accompanying Medication Guide to each patient.

Rx Only 100 Capsules

Usual dosage: Once daily in the evening. See package insert for dosage information.

Each capsule contains 60 mg methylphenidate hydrochloride (equivalent to 52.2 mg of methylphenidate free base)

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from humidity.

Pkg by:
Patheon Puerto Rico, Inc.
Manati, Puerto Rico 00674

Mfg’d for:
Ironshore Pharmaceuticals, Inc.
Cherry Hill, NJ 08002
Principal Display Panel - Jornay PM™ 100 mg Bottle Label

NDC 71376-205-03

Take Only In The Evening

Jornay PM™ CII
[methylphenidate hydrochloride]
Extended-Release Capsules

100 mg

Attention Pharmacist: Dispense the accompanying Medication Guide to each patient.

Rx Only
100 Capsules
**JORNAY PM™ CII**

methylphenidate hydrochloride capsule

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:71376-201</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
<td>DEA Schedule</td>
<td>CII</td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate Hydrochloride</td>
<td>Methylphenidate Hydrochloride</td>
<td>20 mg</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>microcrystalline cellulose</td>
<td></td>
</tr>
<tr>
<td>hypromellose 2910 (5 MPAS)</td>
<td></td>
</tr>
<tr>
<td>ethylcellulose (10 MPAS)</td>
<td></td>
</tr>
<tr>
<td>hydroxypropyl cellulose, unspecified</td>
<td></td>
</tr>
<tr>
<td>dibutyl sebacate (UNII: 4W5lH7FLNY)</td>
<td></td>
</tr>
<tr>
<td>magnesium stearate (UNII: 70097M63B0)</td>
<td></td>
</tr>
<tr>
<td>methacrylic acid - methyl methacrylate copolymer (1:2) (UNII: 5KY6S52577)</td>
<td></td>
</tr>
<tr>
<td>polysorbate 80 (UNII: 6OZP39ZG8H)</td>
<td></td>
</tr>
<tr>
<td>glycercyl monostearate (UNII: 230OU9XXE4)</td>
<td></td>
</tr>
</tbody>
</table>
**Product Characteristics**

<table>
<thead>
<tr>
<th>Color</th>
<th>green (light green), yellow (ivory)</th>
<th>Score</th>
<th>no score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>CAPSULE (CAPSULE)</td>
<td>Size</td>
<td>14mm</td>
</tr>
<tr>
<td>Flavor</td>
<td></td>
<td>Imprint Code</td>
<td>IRONSHORE,20mg</td>
</tr>
<tr>
<td>Contains</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:71376-201-03</td>
<td>100 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>05/20/2019</td>
<td></td>
</tr>
<tr>
<td>Marketing Category</td>
<td>Application Number or Monograph Citation</td>
<td>Marketing Start Date</td>
<td>Marketing End Date</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------</td>
<td>----------------------</td>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>NDA</td>
<td>NDA209311</td>
<td>05/20/2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# JORNAY PM  EXTENDED-RELEASE
methylphenidate hydrochloride capsule

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:71376-202</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
<td>DEA Schedule</td>
<td>CII</td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate Hydrochloride (UNII: 4B3SC438HI)</td>
<td>Methylphenidate Hydrochloride</td>
<td>40 mg</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>microcrystalline cellulose (UNII: OP1R32D61U)</td>
<td></td>
</tr>
<tr>
<td>hypromellose 2910 (5 MPAS) (UNII: R75537T0T4)</td>
<td></td>
</tr>
<tr>
<td>ethylcellulose (10 MPAS) (UNII: 3DYK7UYZ62)</td>
<td></td>
</tr>
<tr>
<td>hydroxypropyl cellulose, unspecified (UNII: 9XZ8H6N6OH)</td>
<td></td>
</tr>
<tr>
<td>dibutyl sebacate (UNII: 4W5IH7FLNY)</td>
<td></td>
</tr>
<tr>
<td>magnesium stearate (UNII: 70097M6I30)</td>
<td></td>
</tr>
<tr>
<td>methacrylic acid - methyl methacrylate copolymer (1:2) (UNII: 5KY68S2577)</td>
<td></td>
</tr>
<tr>
<td>polysorbate 80 (UNII: 60ZP39ZG8H)</td>
<td></td>
</tr>
<tr>
<td>glycercyl monostearate (UNII: 230OU9XXE4)</td>
<td></td>
</tr>
<tr>
<td>talc (UNII: 7SEV7J4RIU)</td>
<td></td>
</tr>
</tbody>
</table>

## Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>green (blue-green), yellow (ivory)</th>
<th>Score</th>
<th>no score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>CAPSULE (CAPSULE)</td>
<td>Size</td>
<td>18 mm</td>
</tr>
<tr>
<td>Flavor</td>
<td></td>
<td>Imprint Code</td>
<td>IRONSHORE;40mg</td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:71376-202-03</td>
<td>100 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>05/20/2019</td>
<td></td>
</tr>
<tr>
<td>Marketing Category</td>
<td>Application Number or Monograph Citation</td>
<td>Marketing Start Date</td>
<td>Marketing End Date</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------</td>
<td>----------------------</td>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>NDA</td>
<td>NDA209311</td>
<td>05/20/2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# JORNAY PM  EXTENDED-RELEASE
methylphenidate hydrochloride capsule

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:71376-203</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORAL</td>
<td>DEA Schedule</td>
<td>CII</td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate Hydrochloride</td>
<td>Methylphenidate Hydrochloride</td>
<td>60 mg</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>microcrystalline cellulose</td>
<td></td>
</tr>
<tr>
<td>hypromellose 2910 (5 MPAS)</td>
<td></td>
</tr>
<tr>
<td>ethyl cellulose (10 MPAS)</td>
<td></td>
</tr>
<tr>
<td>hydroxypropyl cellulose, unspecified</td>
<td></td>
</tr>
<tr>
<td>dibutyl sebacate</td>
<td></td>
</tr>
<tr>
<td>magnesium stearate</td>
<td></td>
</tr>
<tr>
<td>methacrylic acid - methyl methacrylate copolymer (1:2)</td>
<td></td>
</tr>
<tr>
<td>polysorbate 80</td>
<td></td>
</tr>
<tr>
<td>glycercyl monostearate</td>
<td></td>
</tr>
<tr>
<td>talc</td>
<td></td>
</tr>
</tbody>
</table>

## Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>turquoise (powder blue) , white (white)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>CAPSULE (CAPSULE)</td>
</tr>
<tr>
<td>Flavor</td>
<td>no score</td>
</tr>
<tr>
<td>Score</td>
<td>22mm</td>
</tr>
<tr>
<td>Size</td>
<td>60 mg</td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:71376-203-03</td>
<td>100 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>05/20/2019</td>
<td></td>
</tr>
<tr>
<td>Marketing Category</td>
<td>Application Number or Monograph Citation</td>
<td>Marketing Start Date</td>
<td>Marketing End Date</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>NDA</td>
<td>NDA209311</td>
<td>05/20/2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Product Information**

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
</tr>
<tr>
<td>DEA Schedule</td>
<td>CII</td>
</tr>
</tbody>
</table>

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate Hydrochloride</td>
<td>Methylphenidate Hydrochloride</td>
<td>80 mg</td>
</tr>
</tbody>
</table>

**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>microcrystalline cellulose</td>
<td></td>
</tr>
<tr>
<td>hypromellose 2910 (5 MPAS)</td>
<td></td>
</tr>
<tr>
<td>ethylcellulose (10 MPAS)</td>
<td></td>
</tr>
<tr>
<td>hydroxypropyl cellulose, unspecified</td>
<td></td>
</tr>
<tr>
<td>dibutyl sebacate</td>
<td></td>
</tr>
<tr>
<td>magnesium stearate</td>
<td></td>
</tr>
<tr>
<td>methacrylic acid - methyl methacrylate copolymer (1:2)</td>
<td></td>
</tr>
<tr>
<td>polysorbate 80</td>
<td></td>
</tr>
<tr>
<td>glycercyl monostearate</td>
<td></td>
</tr>
<tr>
<td>talc</td>
<td></td>
</tr>
</tbody>
</table>

**Product Characteristics**

<table>
<thead>
<tr>
<th>Color</th>
<th>blue (light blue), white (white)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score</td>
<td>no score</td>
</tr>
<tr>
<td>Shape</td>
<td>CAPSULE (CAPSULE)</td>
</tr>
<tr>
<td>Size</td>
<td>24mm</td>
</tr>
<tr>
<td>Flavor</td>
<td></td>
</tr>
<tr>
<td>Imprint Code</td>
<td>IRONSHORE;80mg</td>
</tr>
</tbody>
</table>

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:71376-204-03</td>
<td>100 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>05/20/2019</td>
<td></td>
</tr>
</tbody>
</table>
**JORNAY PM EXTENDED-RELEASE**
methylphenidate hydrochloride capsule

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:71376-205</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>DEA Schedule</td>
<td>CII</td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate Hydrochloride</td>
<td>Methylphenidate</td>
<td>100 mg</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>microcrystalline cellulose</td>
<td></td>
</tr>
<tr>
<td>hypromellose 2910 (5 MPAS)</td>
<td></td>
</tr>
<tr>
<td>ethylcellulose (10 MPAS)</td>
<td></td>
</tr>
<tr>
<td>hydroxypropyl cellulose, unspecified</td>
<td></td>
</tr>
<tr>
<td>dibutyl sebacate</td>
<td></td>
</tr>
<tr>
<td>magnesium stearate</td>
<td></td>
</tr>
<tr>
<td>methacrylic acid - methyl methacrylate copolymer (1:2)</td>
<td></td>
</tr>
<tr>
<td>polysorbate 80</td>
<td></td>
</tr>
<tr>
<td>glycercyl monostearate</td>
<td></td>
</tr>
<tr>
<td>talc</td>
<td></td>
</tr>
</tbody>
</table>

### Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>blue (dark blue), white (white)</td>
<td>no score</td>
<td>23mm</td>
</tr>
</tbody>
</table>

### Imprint Code

<table>
<thead>
<tr>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRONSHORE;100mg</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:71376-205-03</td>
<td>100 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>05/20/2019</td>
<td></td>
</tr>
<tr>
<td>Marketing Category</td>
<td>Application Number or Monograph Citation</td>
<td>Marketing Start Date</td>
<td>Marketing End Date</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>NDA</td>
<td>NDA209311</td>
<td>05/20/2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
</table>